Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of ruxolitinib cream in children aged 6 to less than 12 years with nonsegmental vitiligo; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Ruxolitinib Cream (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: NonSegmental Vitiligo | Phase 3 | Status: RECRUITING